Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Adenovirus-Encoding E.coli PNP

Gene therapy (Adenoviral vector) · Gene-mediated cytotoxicity · developed by GeoVax

Phase 1/2 Most advanced trial (none active)

GOVX Developer

1 Registered trials

What is Adenovirus-Encoding E.coli PNP?

Ad/PNP is a replication-defective adenoviral vector that delivers the gene for Escherichia coli purine nucleoside phosphorylase. It is studied in recurrent head and neck cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Ad/PNP
Drug type: Gene therapy (Adenoviral vector)
Mechanism: Gene-mediated cytotoxicity
Therapy area: Oncology
Developer: GeoVax, Inc. (GOVX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT03754933	Phase 1/2	Recurrent Head and Neck Cancer	Completed	GOVX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Recurrent Head and Neck Cancer

More from GeoVax

GEO-CM04S1 Phase 2 MVA62B Phase 1

Sources

ClinicalTrials.gov NCT03754933

Updated Oct 11, 2026. Something wrong or missing? Report it on the GOVX page.

Follow GOVX, the company behind Adenovirus-Encoding E.coli PNP

See GOVX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GOVX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z